Rockwell Medical Announces Long-Term, National Supply Agreement With DaVita

Rockwell Medical Announces Long-Term, National Supply Agreement With DaVita

Companies Solidify and Expand Their Business Relationship

WIXOM, Mich., May 8, 2013 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc.
(Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering
innovative products and services targeting end-stage renal disease (ESRD),
chronic kidney disease (CKD), and iron deficiency anemia, announced today they
have signed a multi-year, national product supply agreement with DaVita, the
dialysis division of DaVita HealthCare Partners, Inc. The supply agreement
includes a significant increase in the number of DaVita dialysis clinics that
will purchase product from Rockwell, and covers a five-year period.

"We are pleased to enter into this agreement and expand our business with
DaVita," stated Rob Chioini, Chairman and CEO of Rockwell."This multi-year
supply agreement will significantly expand our business.It includes the
conversion to our CitraPure^® concentrate line and provides an avenue for
future sales of new Rockwell products."

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune
500^® company that, through its operating divisions, provides a variety of
health care services to patient populations throughout the United States and
abroad. A leading provider of kidney care in the United States, DaVita
delivers dialysis services to patients with chronic kidney failure and end
stage renal disease. As of December 31, 2012, DaVita operated or provided
administrative services at 2,000 outpatient dialysis centers located in the
United States serving approximately 153,000 patients. The company also
operated36 outpatient dialysis centers located in five countries outside the
United States.

About Rockwell Medical

Rockwell Medical is a fully-integrated biopharmaceutical company targeting
end-stage renal disease (ESRD) and chronic kidney disease (CKD) with
innovative products and services for the treatment of iron deficiency,
secondary hyperparathyroidism and hemodialysis.

Rockwell's lead drug candidate in late-stage clinical development is for the
treatment of iron deficiency in dialysis patients and is called Soluble Ferric
Pyrophosphate (SFP).SFP delivers iron to the bone marrow of dialysis patients
in a non-invasive, physiologic manner via dialysate during their regular
dialysis treatment. In completed clinical trials to date, SFP has demonstrated
that it can safely deliver sufficient iron to the bone marrow. SFP is nearing
completion of its Phase 3 clinical studies (CRUISE-1 and CRUISE-2) and is
expected to address an estimated $600M U.S. market.

Rockwell is preparing to launch its FDA approved generic drug called
Calcitriol to treat secondary hyperparathyroidism in dialysis
patients.Calcitriol active vitamin D injection is indicated in the management
of hypocalcemia in patients undergoing chronic renal dialysis. It has been
shown to significantly reduce elevated parathyroid hormone levels. Reduction
of PTH has been shown to result in an improvement in renal
osteodystrophy.Rockwell intends to launch Calcitriol as soon as it receives
FDA manufacturing approval, addressing an estimated $350M U.S. market.

Rockwell is also an established manufacturer and leader in delivering
high-quality hemodialysis concentrates/dialysates to dialysis providers and
distributors in the U.S. and abroad.As one of the two major suppliers in the
U.S., Rockwell's products are used to maintain human life, by removing toxins
and replacing critical nutrients in the dialysis patient's
bloodstream.Rockwell has three manufacturing and distribution facilities
located in the U.S. and its operating infrastructure is a ready-made sales and
distribution channel that is able to provide seamless integration into the
commercial market for its drug products, Calcitriol and SFP upon FDA market
approval.

Rockwell's exclusive renal drug therapies support disease management
initiatives to improve the quality of life and care of dialysis patients and
are intended to deliver safe and effective therapy, while decreasing drug
administration costs and improving patient convenience.Rockwell Medical is
developing a pipeline of drug therapies, including extensions of SFP for
indications outside of hemodialysis.Please visit www.rockwellmed.com for more
information. For a demonstration of SFP's unique mechanism of action in
delivering iron via dialysate, please view the animation video at
http://www.rockwellmed.com/collateral/documents/english-us/mode-of-action.html.

The Rockwell Medical Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6773

Certain statements in this press release constitute "forward-looking
statements" within the meaning of the federal securities laws.Words such as
"may," "might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan", "intend" or
similar expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company believes these
forward-looking statements are reasonable, undue reliance should not be placed
on any such forward-looking statements, which are based on information
available to us on the date of this release. These forward looking statements
are based upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set forth in
Rockwell Medical's SEC filings. Thus, actual results could be materially
different.Rockwell Medical expressly disclaims any obligation to update or
alter statements whether as a result of new information, future events or
otherwise, except as required by law.

CONTACT: Michael Rice, Investor Relations at 646-597-6979
         David Connolly, Media Contact at 617-374-8800

Rockwell Medical Technologies, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.